<DOC>
	<DOCNO>NCT01886300</DOCNO>
	<brief_summary>This prospective , multicenter , observational study evaluate sustain response patient HBeAg positive chronic hepatitis B treat Pegasys accord standard care line current local labeling routine clinical practice Vietnam . Eligible patient follow duration treatment 2 year thereafter .</brief_summary>
	<brief_title>An Observational Study Pegasys ( Peginterferon Alfa-2a ) Patients With HBeAg-Positive Chronic Hepatitis B Vietnam</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age HBeAgpositive serologically proven chronic hepatitis B without cirrhosis Elevated serum ALT &gt; ULN ( upper limit normal ) &lt; /= 10 x ULN Patients contraindication Pegasys therapy detail label Written inform consent local regulation allow require Patients receive concomitant therapy telbivudine Coinfection hepatitis A , hepatitis B HIV Pregnant breastfeed woman Patients depression/mental disease Neutrophil baseline &gt; 90.000/mm3 Abnormal T4 TSH</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>